LAGEVRIO Molnupiravir 200mg Capsule for COVID-19 Treatment

Molnupiravir 200mg Capsule

Molnupiravir 200mg Capsule is an experimental antiviral medication authorized for emergency use in the treatment of mild-to-moderate COVID-19. It is designed for adults at high risk for progression to severe COVID-19, including hospitalization or death. This medication is taken orally and is most effective when administered within five days of symptom onset.

• Authorized for emergency use by the FDA
• Reduces risk of hospitalization and death by half in clinical trials
• Administered as 800mg (four 200mg capsules) every 12 hours for 5 days

Used for treating mild-to-moderate COVID-19 in adults at high risk of severe outcomes.

Adults diagnosed with COVID-19 who are at risk of severe symptoms.

Developed by Merck, a leader in pharmaceutical innovation, Molnupiravir represents a significant advancement in COVID-19 treatment options.